CLAIMS

1. Use of fitusiran in the manufacture of a medicament for improving joint function in a hemophilia patient, wherein the medicament is suitable for subcutaneous administration to a hemophilia patient in need thereof, optionally wherein the patient is a hemophilia A or B patient with or without inhibitors.

2. The use according to claim 1, wherein administration of the medicament reduces difficulty in walking or increases mobility.

3. Use of fitusiran in the manufacture of a medicament for improving a joint symptom in a hemophilia patient, wherein the medicament is suitable for subcutaneous administration to a hemophilia patient in need thereof, wherein the joint symptom is selected from joint swelling, painful movement, and joint pain, and optionally wherein the patient is a hemophilia A or B patient with or without inhibitors.

4. Use of fitusiran in the manufacture of a medicament for improving patient-reported outcome (PRO) in a hemophilia patient, wherein the medicament is suitable for subcutaneous administration to a hemophilia patient in need thereof, optionally wherein the patient is a hemophilia A or B patient with or without inhibitors and optionally wherein the PRO is improved in one or more quality-of-life domains.

5. Use of fitusiran in the manufacture of a medicament for improving quality of life (QoL) in a hemophilia patient, wherein the medicament is suitable for subcutaneous administration to a hemophilia patient in need thereof, wherein the QoL is improved in one or

more QoL domains and optionally wherein the patient is a hemophilia A or B patient with or without inhibitors.

6. The use according to any one of claims 1-5, wherein the medicament is suitable for administration at a dose of 40-90 mg of fitusiran.

7. The use according to claim 4 or 5, wherein the one or more QoL domains are domains in a QoL questionnaire, optionally wherein the QoL questionnaire is Haemophilia Quality of Life Questionnaire for Adults (Haem-A-QoL).

8. The use according to claim 7, wherein the administration results in a clinically meaningful improvement indicated by a reduction of 7 or more units (optionally 8 or more, 9 or more, or 10 or more units) in one or more of Total Score, Sports and Leisure domain score, and Physical Health domain score of the Questionnaire.

9. The use according to any one of claims 1-8, wherein the patient is an adult or adolescent patient twelve years or older with hemophilia A or B with or without inhibitors.

10. The use according to any one of claims 1-9, wherein the patient has hemophilia A.

11. The use according to claim 10, wherein the patient has been treated with factor VIII or a bypassing agent (BPA).

12. The use according to claim 11, wherein the patient is with inhibitors, optionally wherein the level of inhibitors is more than 0.6 BU/mL as determined by Bethesda inhibitor assay.

13. The use according to claim 10 or 11, wherein the patient is without inhibitors.

14. The use according to any one of claims 1-9, wherein the patient has hemophilia B.

15. The use according to claim 14, wherein the patient has been treated with factor IX or a BPA.

16. The use according to claim 15, wherein the patient is with inhibitors, optionally wherein the level of inhibitors is more than 0.6 BU/mL as determined by Bethesda inhibitor assay.

17. The use according to claim 14 or 15, wherein the patient is without inhibitors.

18. The use according to any one of claims 11-13 or 15-17, wherein the BPA is activated prothrombin complex concentrates (aPCC) and/or recombinant activated Factor VII (rFVIIa).

19. The use according to any one of claims 1-18, wherein the patient is to be administered a plurality of doses of the medicament, and wherein each dose of the medicament comprises about 50 mg of fitusiran.

20. The use according to of any one of claims 1-18, wherein the patient is to be administered a plurality of doses of the medicament, and wherein each dose of the medicament comprises about 80 mg of fitusiran.

21. The use according to any one of claims 1-20, wherein the medicament comprises fitusiran at a concentration of about 50-200 mg/mL, or optionally at a concentration of about 100 mg/mL, in a phosphate-buffered saline (pH 7).

22. The use according to any one of claims 1-21, wherein the medicament is suitable for administration to the patient about once every four weeks or about once a month.